Alpha-Lipoic Acid
SupplementLast reviewed on July 1, 2025 by SupStaq
Not medical advice. This content is general, evidence-based information and is not a substitute for professional medical advice, diagnosis, or treatment.
The medical evidence is particularly strong for i.v. therapy in diabetic patients [s2], which is less relevant to the general user community (mostly non-diabetics using oral supplementation). Community users more frequently report gastrointestinal issues [c1, c3] and inconsistent effects, which explains the lower community score.
Unlock full information
Dosages, side effects, studies and more, free after registration.
Register for freeRating Scales
TL;DR
Alpha-lipoic acid has its strongest evidence base in diabetic polyneuropathy: a meta-analysis of 4 RCTs (n=1,258) shows significant symptom reduction (SMD -2.26) for IV administration, with oral long-term therapy effective but less robustly supported. For non-diabetics, metabolic benefits are real but modest — without neuropathy or insulin resistance, subjective effects are often negligible. GI side effects are more common than with comparable antioxidants, and the rare but serious Insulin Autoimmune Syndrome (Hirata disease) remains largely unknown in the community. An ongoing EFSA safety review means regulatory changes for high-dose products are possible.
Description
Endogenous antioxidant with mitochondrial function; well-documented efficacy in diabetic neuropathy, evidence for metabolic and neuroprotective effects [s1, s2, s3].
Alpha-lipoic acid (ALA) is a sulfur-containing fatty acid that occurs naturally in the human body and serves as a cofactor for mitochondrial enzyme complexes (pyruvate dehydrogenase, α-ketoglutarate dehydrogenase) [s1]. ALA exists in two stereoisomers: the R-form (naturally occurring) shows approximately twice the bioavailability of the S-form; commercially available dietary supplements typically contain a racemic 50:50 mixture of both forms [s6]. As an antioxidant, ALA directly neutralizes reactive oxygen species (ROS) and regenerates other antioxidants such as vitamin C, vitamin E, and glutathione [s1, s7]. This unique property of being both water- and fat-soluble enables broad protection across various cellular compartments. The best-documented clinical application of ALA is the treatment of symptomatic diabetic polyneuropathy. A meta-analysis of four placebo-controlled RCTs (ALADIN I, ALADIN III, SYDNEY, NATHAN II; n=1,258) demonstrated a significant reduction in the Total Symptom Score (TSS) with i.v. administration of 600 mg daily over 3 weeks [s2]. For long-term oral therapy, the data are less conclusive: a Cochrane analysis concludes that ALA likely shows little or no effect on symptoms of diabetic peripheral neuropathy after six months of treatment [s3]. For metabolic indications (insulin sensitivity, weight), several meta-analyses are available showing moderate effects in overweight individuals and type 2 diabetes [s4, s5]. Initial clinical evidence exists for cognitive and neuroprotective effects, though the data remain limited [s8].
Legal Status (DE)
{'eu_regulatory_note': 'The EFSA is conducting a safety assessment of alpha-lipoic acid (thioctic acid) and the risk of insulin autoimmune syndrome (Hirata disease) on behalf of the European Commission. The procedure is being conducted under Article 8(2) of Regulation (EC) No 1925/2006 on the addition of vitamins, minerals and certain other substances to foods. ', 'source_ids': ['s16']}
Mechanism of Action
Alpha-lipoic acid acts through several complementary mechanisms: 1. Direct antioxidant activity: ALA and its reduced form dihydrolipoic acid (DHLA) react directly with ROS such as superoxide radicals, hydroxyl radicals, hypochlorous acid, peroxyl radicals, and singlet oxygen [s7]. These reactions reduce oxidative cellular damage. 2. Regeneration of other antioxidants: DHLA can convert oxidized glutathione, vitamin C, and vitamin E back to their active (reduced) forms. Additionally, ALA enhances cellular cysteine uptake, thereby increasing glutathione biosynthesis [s1]. 3. Mitochondrial function: ALA serves as a cofactor for pyruvate dehydrogenase and α-ketoglutarate dehydrogenase, two key enzymes of mitochondrial energy production. By inhibiting the Wnt/Ca²⁺ signaling pathway and promoting mitochondrial biogenesis, ALA can improve mitochondrial dysfunction [s1]. 4. Insulin-mimetic effect: ALA activates the insulin signaling pathway (PI3K/Akt cascade) and promotes translocation of the glucose transporter GLUT4 to the cell surface, improving glucose uptake in muscle and adipose cells [s4]. 5. Chelation: ALA and DHLA can complex divalent heavy metal ions (including copper, iron, arsenic, cadmium) and promote their excretion, including from the intracellular compartment [s9]. 6. Anti-inflammatory effects: ALA inhibits NF-κB-dependent signaling pathways and reduces pro-inflammatory cytokines [s1].
Dosing
Diabetische Polyneuropathie (kurzfristige Symptomlinderung)
- Dose
- 600 mg thioctic acid intravenously
- Frequency
- 1× täglich, 5 Tage/Woche
- Route
- oral
- Duration
- 3 Wochen
- Timing
- Infusion over 30 minutes
- With food
- optional
Diabetische Polyneuropathie (orale Langzeittherapie)
- Dose
- 600 mg thioctic acid orally
- Frequency
- 1× täglich
- Route
- oral
- Duration
- mindestens 3–6 Monate
- Timing
- 30–60 minutes before a meal (fasted for better absorption)
- With food
- vermeiden
Metabolisches Syndrom / Insulinsensitivität
- Dose
- 300–600 mg ALA orally
- Frequency
- 1× täglich
- Route
- oral
- Duration
- 8–24 Wochen
- Timing
- Fasted or 30 minutes before eating
- With food
- vermeiden
Allgemeine antioxidative Supplementierung (Nahrungsergänzung)
- Dose
- 200–300 mg racemic ALA or 100–200 mg R-ALA
- Frequency
- 1× täglich
- Route
- oral
- Duration
- fortlaufend
- Timing
- Preferably fasted
- With food
- vermeiden
The EFSA is currently reviewing maximum amounts; existing observational data show acceptable safety at up to 1,200 mg/day over 4 years [s11]. Doses above 600 mg/day as a dietary supplement are subject to increasing regulatory scrutiny [s14]. ALA should not be used in children and adolescents due to insufficient safety data [s9].
The R-form has approximately twice the bioavailability of the S-form; dosages can be reduced accordingly when using R-ALA preparations [s6]. ALA should not be taken simultaneously with minerals (zinc, magnesium, iron) due to competitive absorption [s9].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Gastrointestinale Beschwerden (Übelkeit, Magenschmerzen, Erbrechen) Most common adverse effect with oral intake; intensified at higher doses (>600 mg). Fasted intake may worsen GI tolerability [s11, s9]. | häufig | leicht |
| Hypoglykämie (Blutzuckerabfall) ALA potentiates insulin-mimetic activity and, in combination with antidiabetic agents or insulin, can dangerously lower blood glucose [s4, s9]. | gelegentlich | moderat |
| Hautreaktionen (Juckreiz, Ausschlag, Urtikaria) Allergic skin reactions have been documented in clinical trials and case reports [s9, s11]. | gelegentlich | leicht |
| Insulin Autoimmune Syndrome (Hirata-Syndrom) Rare but serious autoimmune reaction: ALA can trigger the formation of insulin autoantibodies, leading to severe hypoglycemia. EFSA has assessed this risk in a scientific opinion [s12]. Genetic predisposition (HLA-DR4) increases the risk. | selten | schwer |
| Wechselwirkung mit Schilddrüsenmedikamenten (Levothyroxin) A case report in a patient taking levothyroxine showed increased GI adverse effects; ALA may potentially influence thyroid hormone synthesis [s11]. | selten | moderat |
| Uringeruch (schwefelhaltig) A characteristic urine odor may occur due to the sulfur metabolism of ALA; not clinically relevant [s11]. | gelegentlich | leicht |
Contraindications
ALA may increase the risk of insulin autoimmune syndrome; ALA is contraindicated in patients with known predisposition or prior history [s12].
Insufficient safety data for pediatric use; ALA should not be used in children and adolescents [s9].
Animal studies showed no teratogenic effects; however, adequate clinical data for safe use during pregnancy and lactation are lacking [s9, s15].
Impaired renal or hepatic function alters ALA elimination; increased risk of accumulation and adverse effects [s9].
High-dose ALA may theoretically interfere with thiamine (vitamin B1) metabolism; supplement vitamin B1 if thiamine deficiency risk is present [s9].
Interactions
Synergistic
Alpha-lipoic acid and acetyl-L-carnitine act synergistically on mitochondrial metabolism: alpha-lipoic acid, as a cofactor of mitochondrial dehydrogenases, reduces oxidative stress and promotes acetyl-CoA production, while acetyl-L-carnitine optimizes mitochondrial acetyl group transport and supports ATP synthesis. This combined effect can improve mitochondrial function and is of particular relevance in age-related oxidative stress and neurodegenerative processes.
ALA and ALCAR act synergistically on mitochondrial function and reduce oxidative stress. Studies show improved mitochondrial bioenergetics and reduced ROS production with combined intake.
Berberine and ALA complement each other in improving insulin sensitivity and blood glucose regulation. Berberine activates AMPK, while ALA enhances cellular glucose uptake.
ALA and CoQ10 act together as mitochondrial nutrients, supporting cellular energy production and antioxidant protection. Studies show improved exercise performance and mitochondrial function with combined administration.
ALA can chelate iron, potentially affecting its absorption. To ensure optimal absorption of both substances, iron and ALA supplements should be taken at staggered times.
Caution
ALA inhibits biotin activity, as both compounds partially share the same transport mechanisms. With long-term ALA use, concurrent biotin supplementation is recommended to prevent biotin deficiency.
ALA can bind iron as a chelating agent, thereby reducing iron absorption when taken simultaneously. Iron supplements should be taken at a different time from ALA to ensure adequate uptake.
ALA can also chelate zinc and impair its absorption. Staggered administration of zinc supplements and ALA is recommended.
ALA can chelate magnesium and reduce magnesium absorption when taken concomitantly. Staggered administration is therefore recommended.
Studies
Tier A: High Evidence
Outcome: Total Symptom Score (TSS) in diabetic polyneuropathy
Effect Size: SMD -2.26 (95% CI -3.12 to -1.41); significant reduction in neuropathic symptoms
Outcome: Symptoms and functional limitations in diabetic peripheral neuropathy (long-term oral therapy)
Effect Size: Likely little or no effect on symptoms after 6 months
Outcome: Safety and efficacy of oral ALA in diabetic neuropathy
Effect Size: Significant symptom reduction; details in publication
Outcome: BMI and body weight in overweight/obese adults
Effect Size: Significant reduction in BMI and body weight
Outcome: Glycemic parameters and weight in type 2 diabetes
Effect Size: Significant improvement in HbA1c, fasting blood glucose, and body weight
Tier B: Moderate Evidence
Outcome: Cognitive function (processing speed, working memory) following preoperative ALA administration
Effect Size: Significant improvement at 600 mg/day vs. placebo
Outcome: Safety and adverse events at 400–1,200 mg ALA daily
Effect Size: Acceptable safety profile; no serious AEs in healthy subjects
Tier C: Low Evidence
Outcome: Bioavailability of R-ALA vs. racemic ALA by age and sex
Effect Size: R-ALA approximately 2× higher bioavailability than S-ALA; age-dependent differences
Community Evidence
Top reported benefits
- Reduction of tingling and numbness in neuropathy symptoms
- Improved energy metabolism and reduced fatigue
- Blood glucose stabilization (especially in diabetics)
- Mild improvement in cognitive function and concentration
- General antioxidant protection (subjectively perceived)
Top reported issues
- Nausea and stomach pain, particularly when taken on an empty stomach
- Inconsistent effects in non-diabetics
- Strong sulfurous odor of urine
- Dizziness and headaches at higher doses
Several Reddit users report significant gastrointestinal side effects even at moderate doses [c1, c3]. The risk of insulin autoimmune syndrome (Hirata syndrome) is largely unknown within the community [c2]. Users without diabetes frequently report no subjective benefit despite theoretically positive mechanisms. German forums show isolated reports of interactions with thyroid medications [c4].
Scientific Sources
- Alpha-Lipoic Acid: Biological Mechanisms and Health Benefits
Akbari M, Ostadmohammadi V, Lankarani KB, et al. (2024). Antioxidants (MDPI)BDOI - Alpha lipoic acid: advancing insights in diabetic neuropathy through updated systematic review and meta-analysis
Khalid M, Petroianu G, Adem A, et al. (2023). Exploration of Neuroprotective TherapyADOI - Safety and Efficacy of Alpha Lipoic Acid During 4 Years of Observation: A Retrospective, Clinical Trial in Healthy Subjects in Primary Prevention
Mignini F, Capacchietti M, Napolioni V, et al. (2020). NutrientsBDOI - Scientific opinion on the relationship between intake of alpha-lipoic acid (thioctic acid) and the risk of insulin autoimmune syndrome
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) (2021). EFSA JournalAPMID:34122657DOI - ATC N07XB01 - Thioctsäure (Alpha-Liponsäure) - Alpha-Lipon AL 600 Fachinformation
ALIUD PHARMA GmbH (2023). Fachinformation (ALIUD PHARMA / BfArM)ALink - New EU Rules for Food Supplements: Alpha Lipoic Acid under Article 8 Directive 2002/46/EC
Gruppo FarmaImpresa (2025). FarmaImpresa Regulatory ReportBLink - Arzneimittel & Recht: Untersagung des Inverkehrbringens eines Arzneimittels (Alpha-Liponsäure)
Arzneimittel-und-Recht.de Redaktion (2021). Arzneimittel und Recht ArchivBLink - Scientific Opinion on the relationship between intake of alpha-lipoic acid (thioctic acid) and the risk of insulin autoimmune syndrome
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) (2021). CLink - Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis
Ziegler D, Nowak H, Kempler P, et al. (2004). Diabetic MedicineAPMID:14984445DOI - Ist das natürliche Antioxidationsmittel Alpha-Liponsäure besser als keine Behandlung oder eine Scheinbehandlung bei Menschen mit Diabetes und Nervenschäden? (Cochrane Review CD012967)
Cochrane Metabolic and Endocrine Disorders Group (2023). Cochrane Database of Systematic ReviewsADOI - Efficacy and safety of oral alpha-lipoic acid supplementation for type 2 diabetes management: a systematic review and dose-response meta-analysis of randomized trials
Akbari M, Ostadmohammadi V, Tabrizi R, et al. (2022). Endocrine ConnectionsADOI - Alpha-lipoic acid supplementation significantly reduces the risk of obesity in an updated systematic review and dose response meta-analysis of randomised placebo-controlled clinical trials
Vajdi M, Farhangi MA, Nikniaz L (2020). International Journal of Clinical PracticeAPMID:32091656DOI - Age and gender dependent bioavailability of R- and R,S-α-lipoic acid: A pilot study
Carlson DA, Smith AR, Fischer SJ, et al. (2007). Pharmacological ResearchBDOI - Alpha-lipoic acid as a biological antioxidant
Packer L, Witt EH, Tritschler HJ (1995). Free Radical Biology and MedicineBDOI - Alpha-lipoic acid alleviates oxidative stress and brain damage in patients with sevoflurane anesthesia
Liu Y, Zhang X, Wang H, et al. (2025). Frontiers in PharmacologyADOI - Alpha-Lipoic Acid - StatPearls
Ghelani H, Razmovski-Naumovski V, Nammi S (2024). StatPearls Publishing / NCBI BookshelfBLink
Community Sources
Storage
Unopened
Store in a dry, cool place (below 25 °C), protected from direct sunlight and moisture.
Opened
Keep container tightly closed; powder forms are moisture-sensitive. Store at room temperature.
Notes
R-ALA preparations can polymerize upon exposure to heat and turn yellow-brown; such products should not be consumed. Light protection is important as ALA is photosensitive.